The duality of chemokines in heart failure

References

• Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation 2014;129:e28-e292
   PubMed Web of Science ®Google Scholar
• Kapadia S, Torre-Amione G, Yokoyama T, et al. Soluble TNF binding proteins modulate the negative inotropic properties of TNF-alpha in vitro. Am J Physiol 1995;268:H517-25
   Google Scholar
• van der Poll T, van Deventer SJ. Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am 1999;13:413-26; ix
   PubMed Web of Science ®Google Scholar
• Gulick T, Chung MK, Pieper SJ, et al. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci USA 1989;86:6753-7
   PubMed Web of Science ®Google Scholar
• Finkel MS, Hoffman RA, Shen L, et al. Interleukin-6 (IL-6) as a mediator of stunned myocardium. Am J Cardiol 1993;71:1231-2
   PubMed Web of Science ®Google Scholar
• McGowan FXJr, Takeuchi K, del Nido PJ, et al. Myocardial effects of interleukin-2. Transplant Proc 1994;26:209-10
   PubMed Web of Science ®Google Scholar
• Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997;81:627-35
   PubMed Web of Science ®Google Scholar
• Bryant D, Becker L, Richardson J, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998;97:1375-81
   PubMed Web of Science ®Google Scholar
• Sivasubramanian N, Coker ML, Kurrelmeyer KM, et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2001;104:826-31
   PubMed Web of Science ®Google Scholar
• Chung MK, Gulick TS, Rotondo RE, et al. Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction. Circ Res 1990;67:753-63
   PubMed Web of Science ®Google Scholar
• Kadokami T, McTiernan CF, Kubota T, et al. Effects of soluble TNF receptor treatment on lipopolysaccharide-induced myocardial cytokine expression. Am J Physiol Heart Circ Physiol 2001;280:H2281-91
   Web of Science ®Google Scholar
• Yokoyama T, Nakano M, Bednarczyk JL, et al. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997;95:1247-52
   PubMed Web of Science ®Google Scholar
• Kadokami T, McTiernan CF, Kubota T, et al. Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. J Clin Invest 2000;106:589-97
   PubMed Web of Science ®Google Scholar
• Kubota T, Miyagishima M, Alvarez RJ, et al. Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. J Heart Lung Transplant 2000;19:819-24
   PubMed Web of Science ®Google Scholar
• Berthonneche C, Sulpice T, Boucher F, et al. New insights into the pathological role of TNF-alpha in early cardiac dysfunction and subsequent heart failure after infarction in rats. Am J Physiol Heart Circ Physiol 2004;287:H340-50
   Web of Science ®Google Scholar
• Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41
   PubMed Web of Science ®Google Scholar
• Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995;92:1479-86
   PubMed Web of Science ®Google Scholar
• Testa M, Yeh M, Lee P, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996;28:964-71
   PubMed Web of Science ®Google Scholar
• Aukrust P, Ueland T, Muller F, et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998;97:1136-43
   PubMed Web of Science ®Google Scholar
• Kukielka GL, Youker KA, Michael LH, et al. Role of early reperfusion in the induction of adhesion molecules and cytokines in previously ischemic myocardium. Mol Cell Biochem 1995;147:5-12
   PubMed Web of Science ®Google Scholar
• Martin AP, Coronel EC, Sano G, et al. A novel model for lymphocytic infiltration of the thyroid gland generated by transgenic expression of the CC chemokine CCL21. J Immunol 2004;173:4791-8
   PubMed Web of Science ®Google Scholar
• Hong KH, Ryu J, Han KH. Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 2005;105:1405-7
   PubMed Web of Science ®Google Scholar
• Tarzami ST, Cheng R, Miao W, et al. Chemokine expression in myocardial ischemia: MIP-2 dependent MCP-1 expression protects cardiomyocytes from cell death. J Mol Cell Cardiol 2002;34:209-21
   PubMed Web of Science ®Google Scholar
• Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804
   PubMed Web of Science ®Google Scholar
• Thompson MD, Burnham WM, Cole DE. The G protein-coupled receptors: pharmacogenetics and disease. Crit Rev Clin Lab Sci 2005;42:311-92
   PubMed Web of Science ®Google Scholar
• Tang CM, Insel PA. Genetic variation in G-protein-coupled receptors – consequences for G-protein-coupled receptors as drug targets. Expert Opin Ther Targets 2005;9:1247-65
   PubMed Web of Science ®Google Scholar
• Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002;1:727-30
   PubMed Web of Science ®Google Scholar
• Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood 2000;95:3032-43
   PubMed Web of Science ®Google Scholar
• Brouty-Boye D, Pottin-Clemenceau C, Doucet C, et al. Chemokines and CD40 expression in human fibroblasts. Eur J Immunol 2000;30:914-19
   PubMed Web of Science ®Google Scholar
• Gupta SK, Lysko PG, Pillarisetti K, et al. Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J Biol Chem 1998;273:4282-7
   PubMed Web of Science ®Google Scholar
• Schecter AD, Calderon TM, Berman AB, et al. Human vascular smooth muscle cells possess functional CCR5. J Biol Chem 2000;275:5466-71
   PubMed Web of Science ®Google Scholar
• Hohensinner PJ, Kaun C, Rychli K, et al. Monocyte chemoattractant protein (MCP-1) is expressed in human cardiac cells and is differentially regulated by inflammatory mediators and hypoxia. FEBS Lett 2006;580:3532-8
   PubMed Web of Science ®Google Scholar
• Damas JK, Gullestad L, Ueland T, et al. CXC-chemokines, a new group of cytokines in congestive heart failure – possible role of platelets and monocytes. Cardiovasc Res 2000;45:428-36
   PubMed Web of Science ®Google Scholar
• Shioi T, Matsumori A, Kihara Y, et al. Increased expression of interleukin-1 beta and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ Res 1997;81:664-71
   PubMed Web of Science ®Google Scholar
• Seino Y, Ikeda U, Sekiguchi H, et al. Expression of leukocyte chemotactic cytokines in myocardial tissue. Cytokine 1995;7:301-4
   PubMed Web of Science ®Google Scholar
• Behr TM, Wang X, Aiyar N, et al. Monocyte chemoattractant protein-1 is upregulated in rats with volume-overload congestive heart failure. Circulation 2000;102:1315-22
   PubMed Web of Science ®Google Scholar
• Damås JK, Eiken HG, Oie E, et al. Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res 2000;47:778-87
   PubMed Web of Science ®Google Scholar
• Tarzami ST, Miao W, Mani K, et al. Opposing effects mediated by the chemokine receptor CXCR2 on myocardial ischemia-reperfusion injury: recruitment of potentially damaging neutrophils and direct myocardial protection. Circulation 2003;108:2387-92
   PubMed Web of Science ®Google Scholar
• Talvani A, Rocha MO, Barcelos LS, et al. Elevated concentrations of CCL2 and tumor necrosis factor-alpha in chagasic cardiomyopathy. Clin Infect Dis 2004;38:943-50
   PubMed Web of Science ®Google Scholar
• Fuse K, Kodama M, Hanawa H, et al. Enhanced expression and production of monocyte chemoattractant protein-1 in myocarditis. Clin Exp Immunol 2001;124:346-52
   PubMed Web of Science ®Google Scholar
• Damas JK, Gullestad L, Aass H, et al. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure – modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol 2001;38:187-93
   PubMed Web of Science ®Google Scholar
• Kolattukudy PE, Quach T, Bergese S, et al. Myocarditis induced by targeted expression of the MCP-1 gene in murine cardiac muscle. Am J Pathol 1998;152:101-11
   PubMed Web of Science ®Google Scholar
• Hayashidani S, Tsutsui H, Shiomi T, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2003;108:2134-40
   PubMed Web of Science ®Google Scholar
• Devaux B, Scholz D, Hirche A, et al. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 1997;18:470-9
   PubMed Web of Science ®Google Scholar
• Montecucco F, Braunersreuther V, Lenglet S, et al. CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice. Eur Heart J 2012;33:1964-74
   PubMed Web of Science ®Google Scholar
• Kaikita K, Hayasaki T, Okuma T, et al. Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction. Am J Pathol 2004;165:439-47
   PubMed Web of Science ®Google Scholar
• Suffee N, Hlawaty H, Meddahi-Pelle A, et al. RANTES/CCL5-induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans. Angiogenesis 2012;15:727-44
   PubMed Web of Science ®Google Scholar
• Tarzami ST, Calderon TM, Deguzman A, et al. MCP-1/CCL2 protects cardiac myocytes from hypoxia-induced apoptosis by a G(alphai)-independent pathway. Biochem Biophys Res Commun 2005;335:1008-16
   PubMed Web of Science ®Google Scholar
• Liehn EA, Tuchscheerer N, Kanzler I, et al. Double-edged role of the CXCL12/CXCR4 axis in experimental myocardial infarction. J Am Coll Cardiol 2011;58:2415-23
   PubMedGoogle Scholar
• Van Coillie E, Van Damme J, Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev 1999;10:61-86
   PubMed Web of Science ®Google Scholar
• Craig MJ, Loberg RD. CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases. Cancer Metastasis Rev 2006;25:611-19
   PubMed Web of Science ®Google Scholar
• Deshmane SL, Kremlev S, Amini S, et al. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009;29:313-26
   PubMed Web of Science ®Google Scholar
• Rollins BJ. Chemokines. Blood 1997;90:909-28
   PubMed Web of Science ®Google Scholar
• Rollins BJ, Morrison ED, Stiles CD. Cloning and expression of JE, a gene inducible by platelet-derived growth factor and whose product has cytokine-like properties. Proc Natl Acad Sci USA 1988;85:3738-42
   PubMed Web of Science ®Google Scholar
• Kim MS, Day CJ, Morrison NA. MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J Biol Chem 2005;280:16163-9
   PubMed Web of Science ®Google Scholar
• Banisadr G, Gosselin RD, Mechighel P, et al. Highly regionalized neuronal expression of monocyte chemoattractant protein-1 (MCP-1/CCL2) in rat brain: evidence for its colocalization with neurotransmitters and neuropeptides. J Comp Neurol 2005;489:275-92
   PubMed Web of Science ®Google Scholar
• Pype JL, Dupont LJ, Menten P, et al. Expression of monocyte chemotactic protein (MCP)-1, MCP-2, and MCP-3 by human airway smooth-muscle cells. Modulation by corticosteroids and T-helper 2 cytokines. Am J Respir Cell Mol Biol 1999;21:528-36
   PubMed Web of Science ®Google Scholar
• Xia M, Sui Z. Recent developments in CCR2 antagonists. Expert Opin Ther Pat 2009;19:295-303
   PubMed Web of Science ®Google Scholar
• Matsumori A, Furukawa Y, Hashimoto T, et al. Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol 1997;29:419-23
   PubMed Web of Science ®Google Scholar
• Satoh M, Akatsu T, Ishkawa Y, et al. A novel activator of C-C chemokine, FROUNT, is expressed with C-C chemokine receptor 2 and its ligand in failing human heart. J Card Fail 2007;13:114-19
   PubMed Web of Science ®Google Scholar
• Gerszten RE, Mach F, Sauty A, et al. Chemokines, leukocytes, and atherosclerosis. J Lab Clin Med 2000;136:87-92
   PubMed Web of Science ®Google Scholar
• Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998;2:275-81
   PubMed Web of Science ®Google Scholar
• Lehmann MH, Kuhnert H, Muller S, et al. Monocyte chemoattractant protein 1 (MCP-1) gene expression in dilated cardiomyopathy. Cytokine 1998;10:739-46
   PubMed Web of Science ®Google Scholar
• Ono K, Matsumori A, Furukawa Y, et al. Prevention of myocardial reperfusion injury in rats by an antibody against monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest 1999;79:195-203
   PubMed Web of Science ®Google Scholar
• Spoettl T, Hausmann M, Herlyn M, et al. Monocyte chemoattractant protein-1 (MCP-1) inhibits the intestinal-like differentiation of monocytes. Clin Exp Immunol 2006;145:190-9
   PubMed Web of Science ®Google Scholar
• Marisa C, Lucci I, Di Giulio C, et al. MCP-1 and MIP-2 expression and production in BB diabetic rat: effect of chronic hypoxia. Mol Cell Biochem 2005;276:105-11
   PubMed Web of Science ®Google Scholar
• Ragin AB, Wu Y, Storey P, et al. Monocyte chemoattractant protein-1 correlates with subcortical brain injury in HIV infection. Neurology 2006;66:1255-7
   PubMed Web of Science ®Google Scholar
• Flora G, Pu H, Lee YW, et al. Proinflammatory synergism of ethanol and HIV-1 Tat protein in brain tissue. Exp Neurol 2005;191:2-12
   PubMed Web of Science ®Google Scholar
• Sakurai-Yamashita Y, Shigematsu K, Yamashita K, et al. Expression of MCP-1 in the hippocampus of SHRSP with ischemia-related delayed neuronal death. Cell Mol Neurobiol 2006;26:823-31
   PubMed Web of Science ®Google Scholar
• Wang J, Ou ZL, Hou YF, et al. Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential. Oncogene 2006;25:7201-11
   PubMed Web of Science ®Google Scholar
• Braunersreuther V, Montecucco F, Pelli G, et al. Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice. Thromb Haemost 2013;110:807-25
   PubMed Web of Science ®Google Scholar
• Morimoto H, Hirose M, Takahashi M, et al. MCP-1 induces cardioprotection against ischaemia/reperfusion injury: role of reactive oxygen species. Cardiovasc Res 2008;78:554-62
   PubMed Web of Science ®Google Scholar
• Morimoto H, Takahashi M, Izawa A, et al. Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction. Circ Res 2006;99:891-9
   PubMed Web of Science ®Google Scholar
• von Hundelshausen P, Weber KS, Huo Y, et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001;103:1772-7
   PubMed Web of Science ®Google Scholar
• Pattison JM, Nelson PJ, Huie P, et al. RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J Heart Lung Transplant 1996;15:1194-9
   PubMed Web of Science ®Google Scholar
• Bacon K, Baggiolini M, Broxmeyer H, et al. Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res 2002;22:1067-8
   PubMed Web of Science ®Google Scholar
• Cota M, Kleinschmidt A, Ceccherini-Silberstein F, et al. Upregulated expression of interleukin-8, RANTES and chemokine receptors in human astrocytic cells infected with HIV-1. J Neurovirol 2000;6:75-83
   PubMed Web of Science ®Google Scholar
• Shukaliak JA, Dorovini-Zis K. Expression of the beta-chemokines RANTES and MIP-1 beta by human brain microvessel endothelial cells in primary culture. J Neuropathol Exp Neurol 2000;59:339-52
   PubMed Web of Science ®Google Scholar
• John M, Hirst SJ, Jose PJ, et al. Human airway smooth muscle cells express and release RANTES in response to T helper 1 cytokines: regulation by T helper 2 cytokines and corticosteroids. J Immunol 1997;158:1841-7
   PubMed Web of Science ®Google Scholar
• von Luettichau I, Nelson PJ, Pattison JM, et al. RANTES chemokine expression in diseased and normal human tissues. Cytokine 1996;8:89-98
   PubMed Web of Science ®Google Scholar
• Bernardini G, Ribatti D, Spinetti G, et al. Analysis of the role of chemokines in angiogenesis. J Immunol Methods 2003;273:83-101
   PubMed Web of Science ®Google Scholar
• Crola Da Silva C, Lamerant-Fayel N, Paprocka M, et al. Selective human endothelial cell activation by chemokines as a guide to cell homing. Immunology 2009;126:394-404
   PubMed Web of Science ®Google Scholar
• Aizenstein HJ, Nebes RD, Meltzer CC, et al. The relation of White Matter Hyperintensities to implicit learning in healthy older adults. Int J Geriatr Psychiatry 2002;17:664-9
   PubMed Web of Science ®Google Scholar
• Shahrara S, Amin MA, Woods JM, et al. Chemokine receptor expression and in vivo signaling pathways in the joints of rats with adjuvant-induced arthritis. Arthritis Rheum 2003;48:3568-83
   PubMed Web of Science ®Google Scholar
• Tavakkoly-Bazzaz J, Amiri P, Tajmir-Riahi M, et al. RANTES gene mRNA expression and its -403 G/A promoter polymorphism in coronary artery disease. Gene 2011;487:103-6
   PubMed Web of Science ®Google Scholar
• Braunersreuther V, Pellieux C, Pelli G, et al. Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. J Mol Cell Cardiol 2010;48:789-98
   PubMed Web of Science ®Google Scholar
• Bakhiet M, Tjernlund A, Mousa A, et al. RANTES promotes growth and survival of human first-trimester forebrain astrocytes. Nat Cell Biol 2001;3:150-7
   PubMed Web of Science ®Google Scholar
• Wolpe SD, Sherry B, Juers D, et al. Identification and characterization of macrophage inflammatory protein 2. Proc Natl Acad Sci USA 1989;86:612-16
   PubMed Web of Science ®Google Scholar
• Iida N, Grotendorst GR. Cloning and sequencing of a new gro transcript from activated human monocytes: expression in leukocytes and wound tissue. Mol Cell Biol 1990;10:5596-9
   PubMed Web of Science ®Google Scholar
• Pelus LM, Fukuda S. Peripheral blood stem cell mobilization: the CXCR2 ligand GRObeta rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties. Exp Hematol 2006;34:1010-20
   PubMed Web of Science ®Google Scholar
• Moore BB, Keane MP, Addison CL, et al. CXC chemokine modulation of angiogenesis: the importance of balance between angiogenic and angiostatic members of the family. J Investig Med 1998;46:113-20
   PubMed Web of Science ®Google Scholar
• Wu F, Zikusoka M, Trindade A, et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology 2008;135:1624-35.e24
   PubMed Web of Science ®Google Scholar
• Bernhagen J, Krohn R, Lue H, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007;13:587-96
   PubMed Web of Science ®Google Scholar
• Farivar AS, Krishnadasan B, Naidu BV, et al. Alpha chemokines regulate direct lung ischemia-reperfusion injury. J Heart Lung Transplant 2004;23:585-91
   PubMed Web of Science ®Google Scholar
• Montecucco F, Lenglet S, Braunersreuther V, et al. Single administration of the CXC chemokine-binding protein Evasin-3 during ischemia prevents myocardial reperfusion injury in mice. Arterioscler Thromb Vasc Biol 2010;30:1371-7
   PubMed Web of Science ®Google Scholar
• Zhu HL, Wei X, Qu SL, et al. Ischemic postconditioning protects cardiomyocytes against ischemia/reperfusion injury by inducing MIP2. Exp Mol Med 2011;43:437-45
   PubMed Web of Science ®Google Scholar
• Murdoch C. CXCR4: chemokine receptor extraordinaire. Immunol Rev 2000;177:175-84
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998;19:568-74
   PubMedGoogle Scholar
• Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996;382:829-33
   PubMed Web of Science ®Google Scholar
• Salcedo R, Wasserman K, Young HA, et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 1999;154:1125-35
   PubMed Web of Science ®Google Scholar
• Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996;382:635-8
   PubMed Web of Science ®Google Scholar
• Zou YR, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998;393:595-9
   PubMed Web of Science ®Google Scholar
• Ma Q, Jones D, Borghesani PR, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA 1998;95:9448-53
   PubMed Web of Science ®Google Scholar
• Balabanian K, Lagane B, Infantino S, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 2005;280:35760-6
   PubMed Web of Science ®Google Scholar
• Levoye A, Balabanian K, Baleux F, et al. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009;113:6085-93
   PubMed Web of Science ®Google Scholar
• Deichmann M, Kronenwett R, Haas R. Expression of the human immunodeficiency virus type-1 coreceptors CXCR-4 (fusin, LESTR) and CKR-5 in CD34+ hematopoietic progenitor cells. Blood 1997;89:3522-8
   PubMed Web of Science ®Google Scholar
• Pablos JL, Amara A, Bouloc A, et al. Stromal-cell derived factor is expressed by dendritic cells and endothelium in human skin. Am J Pathol 1999;155:1577-86
   PubMed Web of Science ®Google Scholar
• Heesen M, Berman MA, Benson JD, et al. Cloning of the mouse fusin gene, homologue to a human HIV-1 co-factor. J Immunol 1996;157:5455-60
   PubMed Web of Science ®Google Scholar
• Banisadr G, Skrzydelski D, Kitabgi P, et al. Highly regionalized distribution of stromal cell-derived factor-1/CXCL12 in adult rat brain: constitutive expression in cholinergic, dopaminergic and vasopressinergic neurons. Eur J Neurosci 2003;18:1593-606
   PubMed Web of Science ®Google Scholar
• Banisadr G, Rostene W, Kitabgi P, et al. Chemokines and brain functions. Curr Drug Targets Inflamm Allergy 2005;4:387-99
   PubMedGoogle Scholar
• Pyo RT, Sui J, Dhume A, et al. CXCR4 modulates contractility in adult cardiac myocytes. J Mol Cell Cardiol 2006;41:834-44
   PubMed Web of Science ®Google Scholar
• Zhang M, Mal N, Kiedrowski M, et al. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J 2007;21:3197-207
   PubMed Web of Science ®Google Scholar
• Dai S, Yuan F, Mu J, et al. Chronic AMD3100 antagonism of SDF-1alpha-CXCR4 exacerbates cardiac dysfunction and remodeling after myocardial infarction. J Mol Cell Cardiol 2010;49:587-97
   PubMed Web of Science ®Google Scholar
• Chen J, Chemaly E, Liang L, et al. Effects of CXCR4 gene transfer on cardiac function after ischemia-reperfusion injury. Am J Pathol 2010;176:1705-15
   PubMed Web of Science ®Google Scholar
• Moore MA, Hattori K, Heissig B, et al. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann N Y Acad Sci 2001;938:36-45; discussion 45-7
   PubMed Web of Science ®Google Scholar
• Hiasa K, Ishibashi M, Ohtani K, et al. Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation 2004;109:2454-61
   PubMed Web of Science ®Google Scholar
• Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-7
   PubMed Web of Science ®Google Scholar
• Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-8
   PubMed Web of Science ®Google Scholar
• Currie PF, Goldman JH, Caforio AL, et al. Cardiac autoimmunity in HIV related heart muscle disease. Heart 1998;79:599-604
   PubMed Web of Science ®Google Scholar
• Barbaro G, Di Lorenzo G, Grisorio B, et al. Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators. AIDS Res Hum Retroviruses 1998;14:1071-7
   PubMed Web of Science ®Google Scholar
• Herskowitz A, Willoughby SB, Baughman KL, et al. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases. Ann Intern Med 1992;116:311-13
   PubMed Web of Science ®Google Scholar
• Barbaro G, Di Lorenzo G, Grisorio B, et al. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti da AIDS. N Engl J Med 1998;339:1093-9
   PubMed Web of Science ®Google Scholar
• Moroni M, Antinori S. HIV and direct damage of organs: disease spectrum before and during the highly active antiretroviral therapy era. AIDS 2003;17(Suppl 1):S51-64
   Google Scholar
• Gulino AV. WHIM syndrome: a genetic disorder of leukocyte trafficking. Curr Opin Allergy Clin Immunol 2003;3:443-50
   PubMed Web of Science ®Google Scholar
• Zuelzer WW. “Myelokathexis” – a new form of chronic granulocytopenia. Report of a case. N Engl J Med 1964;270:699-704
   PubMed Web of Science ®Google Scholar
• Hernandez PA, Gorlin RJ, Lukens JN, et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet 2003;34:70-4
   PubMed Web of Science ®Google Scholar
• Taniuchi S, Yamamoto A, Fujiwara T, et al. Dizygotic twin sisters with myelokathexis: mechanism of its neutropenia. Am J Hematol 1999;62:106-11
   PubMed Web of Science ®Google Scholar
• Balabanian K, Harriague J, Decrion C, et al. CXCR4-tropic HIV-1 envelope glycoprotein functions as a viral chemokine in unstimulated primary CD4+ T lymphocytes. J Immunol 2004;173:7150-60
   PubMed Web of Science ®Google Scholar
• Bachelerie F. CXCL12/CXCR4-axis dysfunctions: markers of the rare immunodeficiency disorder WHIM syndrome. Dis Markers 2010;29:189-98
   PubMed Web of Science ®Google Scholar
• Badolato R, Dotta L, Tassone L, et al. Tetralogy of Fallot is an uncommon manifestation of warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. J Pediatr 2012;161:763-5
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG, Entman ML. Targeting the chemokines in myocardial inflammation. Circulation 2004;110:1341-2
   PubMed Web of Science ®Google Scholar
• Limbourg FP, Ringes-Lichtenberg S, Schaefer A, et al. Haematopoietic stem cells improve cardiac function after infarction without permanent cardiac engraftment. Eur J Heart Fail 2005;7:722-9
   PubMed Web of Science ®Google Scholar
• Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003;114:763-76
   PubMed Web of Science ®Google Scholar
• Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001;7:430-6
   PubMed Web of Science ®Google Scholar
• Hughes S. Cardiac stem cells. J Pathol 2002;197:468-78
   PubMed Web of Science ®Google Scholar
• Britten MB, Abolmaali ND, Assmus B, et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation 2003;108:2212-18
   PubMed Web of Science ®Google Scholar
• Laflamme MA, Zbinden S, Epstein SE, et al. Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanisms. Annu Rev Pathol 2007;2:307-39
   PubMed Web of Science ®Google Scholar
• Jain M, DerSimonian H, Brenner DA, et al. Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation 2001;103:1920-7
   PubMed Web of Science ®Google Scholar
• Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-5
   PubMed Web of Science ®Google Scholar
• Murry CE, Soonpaa MH, Reinecke H, et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 2004;428:664-8
   PubMed Web of Science ®Google Scholar
• Toma C, Pittenger MF, Cahill KS, et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002;105:93-8
   PubMed Web of Science ®Google Scholar
• Oh H, Bradfute SB, Gallardo TD, et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA 2003;100:12313-18
   PubMed Web of Science ®Google Scholar
• Mummery C, Ward-van Oostwaard D, et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 2003;107:2733-40
   PubMed Web of Science ®Google Scholar
• Mirotsou M, Jayawardena TM, Schmeckpeper J, et al. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Mol Cell Cardiol 2011;50:280-9
   PubMed Web of Science ®Google Scholar
• Wang WE, Chen X, Houser SR, et al. Potential of cardiac stem/progenitor cells and induced pluripotent stem cells for cardiac repair in ischaemic heart disease. Clin Sci (Lond) 2013;125:319-27
   PubMed Web of Science ®Google Scholar
• Bolli R, Chugh AR, D’Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 2011;378:1847-57
   PubMed Web of Science ®Google Scholar
• Makkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet 2012;379:895-904
   PubMed Web of Science ®Google Scholar
• AutoLogous Human CArdiac-Derived Stem Cell to Treat Ischemic cArdiomyopathy (ALCADIA). Available from: https://clinicaltrials.gov/ct2/show/NCT00981006
   Google Scholar
• Kamihata H, Matsubara H, Nishiue T, et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation 2001;104:1046-52
   PubMed Web of Science ®Google Scholar
• Takahashi M, Li TS, Suzuki R, et al. Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. Am J Physiol Heart Circ Physiol 2006;291:H886-93
   PubMed Web of Science ®Google Scholar
• Matsumoto R, Omura T, Yoshiyama M, et al. Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler Thromb Vasc Biol 2005;25:1168-73
   PubMed Web of Science ®Google Scholar
• Li TS, Cheng K, Malliaras K, et al. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J Am Coll Cardiol 2012;59:942-53
   PubMed Web of Science ®Google Scholar
• Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 in Adults With Ischemic Heart Failure. Available from: https://clinicaltrials.gov/ct2/show/NCT01082094
   Google Scholar
• Penn MS, Mendelsohn FO, Schaer GL, et al. An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure. Circ Res 2013;112:816-25
   PubMed Web of Science ®Google Scholar
• Hou D, Youssef EA, Brinton TJ, et al. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation 2005;112:I150-6
   PubMed Web of Science ®Google Scholar
• Freyman T, Polin G, Osman H, et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 2006;27:1114-22
   PubMed Web of Science ®Google Scholar
• Segers VF, Tokunou T, Higgins LJ, et al. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 2007;116:1683-92
   PubMed Web of Science ®Google Scholar
• Projahn D, Simsekyilmaz S, Singh S, et al. Controlled intramyocardial release of engineered chemokines by biodegradable hydrogels as a treatment approach of myocardial infarction. J Cell Mol Med 2014;18:790-800
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17
   PubMed Web of Science ®Google Scholar
• Mocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010;102:493-501
   PubMed Web of Science ®Google Scholar
• Tsuruoka N, Sugiyama M, Tawaragi Y, et al. Inhibition of in vitro angiogenesis by lymphotoxin and interferon-gamma. Biochem Biophys Res Commun 1988;155:429-35
   PubMed Web of Science ®Google Scholar
• Wagner TC, Velichko S, Chesney SK, et al. Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors. Int J Cancer 2004;111:32-42
   PubMed Web of Science ®Google Scholar
• Lee ME, Miller WL, Edwards BS, et al. Role of endogenous atrial natriuretic factor in acute congestive heart failure. J Clin Invest 1989;84:1962-6
   PubMed Web of Science ®Google Scholar
• Redfield MM, Aarhus LL, Wright RS, et al. Cardiorenal and neurohumoral function in a canine model of early left ventricular dysfunction. Circulation 1993;87:2016-22
   PubMed Web of Science ®Google Scholar
• Sinagra G, Gavazzi A. [The ACCLAIM trial]. G Ital Cardiol (Rome) 2008;9:455-60
   PubMedGoogle Scholar
• Munger MA, Johnson B, Amber IJ, et al. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996;77:723-7
   PubMed Web of Science ®Google Scholar
• Garcia AG, Wilson RM, Heo J, et al. Interferon-gamma ablation exacerbates myocardial hypertrophy in diastolic heart failure. Am J Physiol Heart Circ Physiol 2012;303:H587-96
   Web of Science ®Google Scholar
• Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40
   PubMed Web of Science ®Google Scholar
• Louis A, Cleland JG, Crabbe S, et al. Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001;3:381-7
   PubMed Web of Science ®Google Scholar
• Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002;86:123-30
   PubMed Web of Science ®Google Scholar
• Coletta AP, Clark AL, Banarjee P, et al. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail 2002;4:559-61
   PubMed Web of Science ®Google Scholar
• Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-602
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37
   PubMed Web of Science ®Google Scholar
• Keystone E, Heijde D, Mason DJr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68:805-11
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:96-109.e1
   PubMed Web of Science ®Google Scholar